Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647337 | 0.90 | ALDH1A1 (0.47) | IMPDH2IMPDH1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11822663 | 0.85 | BRD4 (0.47) | KDM4EALDH1A1HSD17B10BRD4NR4A2 | |
| SCHEMBL70381 | 0.84 | BRD4 (0.59) | KDM4EALDH1A1HSD17B10BRD4NR4A2 | |
| SCHEMBL29434198 | 0.84 | BRD4 (0.59) | KDM4EALDH1A1HSD17B10BRD4NR4A2 | |
| SCHEMBL13209656 | 0.81 | IMPDH2 (0.49) | IMPDH2IMPDH1KDM4EALDH1A1BRD4 | |
| SCHEMBL7676590 | 0.80 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HSD17B10BRD4NR4A2 | |
| SCHEMBL22890170 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL5754801 | 0.79 | SLC22A12 (0.49) | IMPDH2IMPDH1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL181067 | 0.79 | ALDH1A1 (0.55) | KDM4EALDH1A1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL7672835 | 0.78 | SMN1; SMN2 (0.47) | KDM4EALDH1A1HSD17B10BRD4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | IMPDH2 2463/4885IMPDH1 1972/4885KDM4E 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.